In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

The medication segment was the largest in 2022, favored for its cost-effectiveness and common use as a first-line treatment. .Centriacinar Emphysema Growth: The centriacinar segment, primarily linked ...